Scholarlink

<p>This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO trajectories by treatment group, idecabtagene vicleucel (ide-cel) vs. ciltacabtagene autoleucel (cilta-cel). Participants completed health-related quality of life (HRQOL) and symptom surveys at enrollment/baseline (pre-lymphodepletion), infusion day(D)0, D7, D14, D21, D30, D60, and D90. Piecewise growth curve models assessed PRO trajectories pre-D7 and post-D7. Among 99 participants, ide-cel recipients (<i>n</i> = 49) were older than cilta-cel recipients (<i>n</i> = 50) (median 73 vs. 64 years, <i>p</i> &lt; 0.001). Many PROs worsened pre-D7 and improved post-D7, including overall HRQOL, physical well-being, functional well-being, fatigue, physical function, and social function (<i>p</i>-values &lt; 0.05). Several PROs were stable pre-D7 and improved post-D7, including anxiety, sleep disturbance, pain interference, and pain intensity (<i>p</i>-values &lt; 0.05). There were differences between groups in the trajectories of social well-being pre-D7 (<i>p</i> = 0.01) and cognitive function post-D7 (<i>p</i> = 0.001). Patients with RRMM receiving standard of care CAR-T had similar PRO trajectories regardless of CAR-T type, with most PROs initially worsening or stable before significantly improving post-treatment. Future studies should investigate potential differences by treatment for social well-being and cognitive function as well as PRO trajectories beyond D90 post-treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Laura B. Oswald,
  • Xiaoyin Li,
  • Lisa M. Gudenkauf,
  • Gabe De Avila,
  • David Scheiber-Camoretti,
  • Brent J. Small,
  • Brian D. Gonzalez,
  • Aasha I. Hoogland,
  • Oanh Nguyen,
  • Yvelise Rodriguez,
  • Sylvia L. Crowder,
  • Nathan H. Parker,
  • Tiffany L. Carson,
  • Christine E. Vinci,
  • Rachid C. Baz,
  • Kenneth H. Shain,
  • Brandon Blue,
  • Ariel Grajales-Cruz,
  • Kristy Matte,
  • Brandon Kale,
  • David Kaldas,
  • Fabiana Perna,
  • Melissa Alsina,
  • Ciara L. Freeman,
  • Omar Castaneda Puglianini,
  • Taiga Nishihori,
  • Hien Liu,
  • Frederick L. Locke,
  • Heather S. L. Jim,
  • Lauren C. Peres,
  • Doris K. Hansen

摘要

This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO trajectories by treatment group, idecabtagene vicleucel (ide-cel) vs. ciltacabtagene autoleucel (cilta-cel). Participants completed health-related quality of life (HRQOL) and symptom surveys at enrollment/baseline (pre-lymphodepletion), infusion day(D)0, D7, D14, D21, D30, D60, and D90. Piecewise growth curve models assessed PRO trajectories pre-D7 and post-D7. Among 99 participants, ide-cel recipients (n = 49) were older than cilta-cel recipients (n = 50) (median 73 vs. 64 years, p < 0.001). Many PROs worsened pre-D7 and improved post-D7, including overall HRQOL, physical well-being, functional well-being, fatigue, physical function, and social function (p-values < 0.05). Several PROs were stable pre-D7 and improved post-D7, including anxiety, sleep disturbance, pain interference, and pain intensity (p-values < 0.05). There were differences between groups in the trajectories of social well-being pre-D7 (p = 0.01) and cognitive function post-D7 (p = 0.001). Patients with RRMM receiving standard of care CAR-T had similar PRO trajectories regardless of CAR-T type, with most PROs initially worsening or stable before significantly improving post-treatment. Future studies should investigate potential differences by treatment for social well-being and cognitive function as well as PRO trajectories beyond D90 post-treatment.